R&D Systems™ Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera Protein, CF

Extensive quality control produces industry leading bioactivity and lot-to-lot consistency that instills confidence in results and ensures reproducibility. Applications: Bioactivity

Supplier:  R&D Systems™ 2017T2050

Catalog No. 2017T2050

Description

Measured by its ability to support the adhesion of HSB2 human peripheral blood acute lymphoblastic leukemia cells. Immobilized Recombinant Human LILRB1/CD85j/ILT2 Fc Chimera at 5 μg/mL, 100 μL/well can support 60-80% HSB2 cell adhesion, when 1 x 105 cells were added in each well of a 96-well plate.

Specifications

• Accession Number: Q8NHL6
• Formulation: Lyophilized from a 0.2 µm filtered solution in PBS.
• Molecular Weight: M.W. (Observed): 106 kDa, reducing conditions; M.W. (theoretical): 73.8 kDa (monomer)
• Purity: >90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
• Source: Mouse myeloma cell line, NS0-derived human LILRB1/CD85j/ILT2 protein Human LILRB1/CD85j/ILT2 (Gly24-His458) (N-terminus) Accession # Q8NHL6 IEGRMD Human IgG1 (Pro100-Lys330) (C-terminus)
• Structural Form: Disulfide-linked homodimer
• Gene Symbol: LILRB1
• Recombinant: Yes
• Protein: ILT2/CD85j/LILRB1

• For Use With (Application): Bioactivity
• Gene ID (Entrez): 10859
• Name: ILT2/CD85j Fc Chimera
• Quantity: 50 µg
• Storage Requirements: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20°C to -70°C as supplied. 1 month, 2°C to 8°C under sterile conditions after reconstitution. 3 months, -20°C to -70°C under sterile conditions after reconstitution.
• Endotoxin Concentration: <0.10 EU / 1 µg of the protein by the LAL method.
• Conjugate: Unconjugated
• Reconstitution: Reconstitute at 100 µg/mL in sterile PBS.